| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H22N4O3 |
| Molecular Weight | 366.4137 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCNC(=O)C1=NN=C2C(=CC=CC2=C1N)C3=CC(OC)=CC=C3OC
InChI
InChIKey=NVWCZRPXYVDQEE-UHFFFAOYSA-N
InChI=1S/C20H22N4O3/c1-4-10-22-20(25)19-17(21)14-7-5-6-13(18(14)23-24-19)15-11-12(26-2)8-9-16(15)27-3/h5-9,11H,4,10H2,1-3H3,(H2,21,23)(H,22,25)
| Molecular Formula | C20H22N4O3 |
| Molecular Weight | 366.4137 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AZD6280 was invented by AstraZeneca as a selective gamma-aminobutyric acid A receptor modulator with higher efficacy at the α2,3 subtypes (GABA-A(α2/3)). This drug participated in trials phase I for the treatment of generalized anxiety disorders, but AstraZeneca discontinued development of AZD 6280.
